3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
gadobenic acid
2
XENP 1595
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
veliparib
1
interferon gamma-1b
1
glutathione pegylated liposomal doxorubicin
1
gadoteridol
1
elacestrant
1
abemaciclib
1
Trastuzumab
1
Temozolomide
1
RAD1901
1
Oncolytic Virotherapy
1
Interferon-gamma
1
Immunotherapy
1
Craniotomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Central Nervous System Diseases
×
Interferon-gamma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled